Join Growin Stock Community!

Agilent technologies, inc.A.US Overview

US StockHealthcare
(No presentation for A)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

A AI Insights

A Overall Performance

A AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

A Recent Performance

-2.51%

Agilent technologies, inc.

0.05%

Avg of Sector

-0.31%

S&P500

A PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

A Key Information

A Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

A Profile

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.

Price of A

A FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

A Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
4.55
PE Ratio (TTM)
26.50
Forward PE
19.04
PS Ratio (TTM)
4.87
PB Ratio
5.08
Price-to-FCF
33.78
METRIC
VALUE
vs. INDUSTRY
Gross Margin
52.23%
Net Margin
18.26%
Revenue Growth (YoY)
8.14%
Profit Growth (YoY)
4.65%
3-Year Revenue Growth
0.79%
3-Year Profit Growth
-0.76%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
4.55
PE Ratio (TTM)
26.50
Forward PE
19.04
PS Ratio (TTM)
4.87
PB Ratio
5.08
Price-to-FCF
33.78
Gross Margin
52.23%
Net Margin
18.26%
Revenue Growth (YoY)
8.14%
Profit Growth (YoY)
4.65%
3-Year Revenue Growth
0.79%
3-Year Profit Growth
-0.76%

  • When is A's latest earnings report released?

    The most recent financial report for Agilent technologies, inc. (A) covers the period of 2026Q1 and was published on 2026/01/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating A's short-term business performance and financial health. For the latest updates on A's earnings releases, visit this page regularly.

  • Where does A fall in the P/E River chart?

    According to historical valuation range analysis, Agilent technologies, inc. (A)'s current price-to-earnings (P/E) ratio is 31.05, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of A?

    According to the latest financial report, Agilent technologies, inc. (A) reported an Operating Profit of 353M with an Operating Margin of 19.63% this period, representing a decline of 6.12% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is A's revenue growth?

    In the latest financial report, Agilent technologies, inc. (A) announced revenue of 1.8B, with a Year-Over-Year growth rate of 6.96%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does A have?

    As of the end of the reporting period, Agilent technologies, inc. (A) had total debt of 3.35B, with a debt ratio of 0.26. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does A have?

    At the end of the period, Agilent technologies, inc. (A) held Total Cash and Cash Equivalents of 1.76B, accounting for 0.14 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does A go with three margins increasing?

    In the latest report, Agilent technologies, inc. (A) achieved the “three margins increasing” benchmark, with a gross margin of 52.61%%, operating margin of 19.63%%, and net margin of 16.96%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess A's profit trajectory and future growth potential.

  • Is A's EPS continuing to grow?

    According to the past four quarterly reports, Agilent technologies, inc. (A)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 1.08. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of A?

    Agilent technologies, inc. (A)'s Free Cash Flow (FCF) for the period is 175M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 47.6% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of A?

    The latest valuation data shows Agilent technologies, inc. (A) has a Price-To-Earnings (PE) ratio of 31.05 and a Price/Earnings-To-Growth (PEG) ratio of -1.06. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.